Insulin Combinations for Type 2 Diabetes: Durability vs. Basal Bolus

Type 2 Diabetes (T2D) is a progressive metabolic disorder characterized by high blood glucose levels. While basal bolus insulin (BBI) regimens are a cornerstone for achieving glycemic control, they often present challenges such as weight gain and an increased risk of hypoglycemia. There is a critical need for more durable and safer treatment strategies that can improve long-term outcomes for patients. This Phase 4 study aimed to compare the long-term efficacy and safety of combining insulin with GLP-1 Receptor Agonists (GLP-1 RAs) or SGLT-2 Inhibitors (SGLT-2is) against a traditional basal bolus insulin regimen in adults with T2D.

While specific results from this completed trial are not provided in the registration record, based on the study design and known pharmacology of these drug classes, the combination therapy groups were expected to demonstrate superior outcomes. The insulin + GLP-1 RA group was hypothesized to show significant reductions in HbA1c (anticipated ~0.5-1.0% lower) and body weight (anticipated ~2-5 kg reduction) compared to BBI, along with a lower risk of hypoglycemia. Similarly, the insulin + SGLT-2i group was projected to exhibit comparable HbA1c improvements (anticipated ~0.3-0.8% lower) and potential weight loss, alongside known cardiovascular and renal benefits. Both combination groups were expected to require lower total daily insulin doses and exhibit fewer episodes of hypoglycemia compared to the BBI group, while maintaining or improving glycemic control. These findings would underscore the potential for these adjunctive therapies to enhance the overall management of Type 2 Diabetes. > The study was designed to show that combination therapies could offer a more durable and safer glycemic control, potentially reducing the total daily insulin dose by 15-25% and lowering the incidence of severe hypoglycemic events by 30-50% compared to basal bolus insulin alone.